B-intervention	0	6	Weekly
I-intervention	7	17	paclitaxel
I-intervention	17	18	/
I-intervention	18	29	carboplatin
I-intervention	29	30	/
I-intervention	30	41	trastuzumab
I-intervention	42	49	therapy
O	50	58	improves
O	59	69	pathologic
O	70	78	complete
O	79	88	remission
O	89	91	in
O	92	102	aggressive
O	103	107	HER2
O	107	108	-
O	108	116	positive
O	117	123	breast
O	124	131	cancers
O	131	132	,
O	133	143	especially
O	144	146	in
O	147	154	luminal
O	154	155	-
O	155	156	B
O	157	164	subtype
O	164	165	,
O	166	174	compared
O	175	179	with
O	180	181	a
O	182	186	once
O	186	187	-
O	187	192	every
O	192	193	-
O	193	194	3
O	194	195	-
O	195	200	weeks
O	201	209	schedule
O	209	210	.

O	211	214	The
O	215	223	efficacy
O	224	227	and
O	228	240	tolerability
O	241	243	of
O	244	247	two
O	248	257	different
O	258	267	schedules
O	268	270	of
O	271	281	paclitaxel
O	281	282	,
O	283	294	carboplatin
O	294	295	,
O	296	299	and
O	300	311	trastuzumab
O	312	313	(
O	313	318	PCarH
O	318	319	)
O	320	323	for
O	324	328	HER2
O	328	329	-
O	329	337	positive
O	337	338	,
O	339	346	locally
O	347	357	aggressive
O	358	359	(
O	359	364	stage
O	365	368	IIB
O	368	369	-
O	369	373	IIIC
O	373	374	)
O	375	381	breast
O	382	389	cancers
O	390	394	were
O	395	404	evaluated
O	405	407	in
O	408	412	this
O	413	418	phase
O	419	421	II
O	422	427	trial
O	427	428	.

O	429	437	Patients
O	438	442	were
O	443	451	randomly
O	452	460	assigned
O	461	463	to
O	464	471	receive
O	472	478	either
O	479	485	weekly
O	486	487	(
O	487	489	12
O	490	495	doses
O	496	500	over
O	501	503	16
O	504	509	weeks
O	509	510	)
O	511	513	or
O	514	518	once
O	518	519	-
O	519	524	every
O	524	525	-
O	525	526	3
O	526	527	-
O	527	532	weeks
O	533	534	(
O	534	535	4
O	536	541	doses
O	542	546	over
O	547	549	12
O	550	555	weeks
O	555	556	)
O	557	566	treatment
O	566	567	.

O	568	571	The
O	572	579	primary
O	580	588	endpoint
O	589	592	was
B-outcome-Measure	593	603	pathologic
I-outcome-Measure	604	612	complete
I-outcome-Measure	613	622	remission
I-outcome-Measure	623	624	(
I-outcome-Measure	624	627	pCR
I-outcome-Measure	627	628	)
I-outcome-Measure	629	631	in
I-outcome-Measure	632	635	the
I-outcome-Measure	636	642	breast
I-outcome-Measure	643	646	and
I-outcome-Measure	647	653	axilla
O	653	654	.

O	655	657	To
O	658	664	detect
O	665	667	an
O	668	675	assumed
O	676	678	35
O	678	679	%
O	680	683	pCR
O	684	692	absolute
O	693	703	difference
O	704	711	between
O	712	715	the
O	716	719	two
O	720	729	schedules
O	729	730	,
O	731	732	a
O	733	740	minimum
O	741	743	of
O	744	746	26
O	747	757	assessable
O	758	766	patients
O	767	769	in
O	770	774	each
O	775	780	group
O	781	784	was
O	785	793	required
O	794	795	(
O	795	798	two
O	798	799	-
O	799	804	sided
O	805	806	α
O	807	808	=
O	809	810	0
O	810	811	.
O	811	813	05
O	813	814	,
O	815	816	β
O	817	818	=
O	819	820	0
O	820	821	.
O	821	822	2
O	822	823	)
O	823	824	.

O	825	826	A
O	827	832	total
O	833	835	of
B-total-participants	836	838	56
O	839	847	patients
O	848	852	were
O	853	861	enrolled
O	862	863	(
O	863	869	weekly
O	870	875	group
O	875	876	,
O	877	878	n
O	879	880	=
B-intervention-participants	881	883	29
O	883	884	;
B-control	885	890	every
I-control	890	891	-
I-control	891	892	3
I-control	892	893	-
I-control	893	898	weeks
I-control	899	904	group
O	904	905	,
O	906	907	n
O	908	909	=
B-control-participants	910	912	27
O	912	913	)
O	913	914	.

O	915	917	In
O	918	921	the
O	922	928	intent
O	928	929	-
O	929	931	to
O	931	932	-
O	932	937	treat
O	938	946	analysis
O	946	947	,
B-outcome	948	951	pCR
I-outcome	952	954	in
I-outcome	955	958	the
I-outcome	959	965	breast
I-outcome	965	966	/
I-outcome	966	972	axilla
O	973	977	were
O	978	983	found
O	984	986	in
O	987	989	31
O	990	998	patients
O	999	1000	(
O	1000	1002	55
O	1002	1003	%
O	1003	1004	;
O	1005	1007	95
O	1007	1008	%
O	1009	1019	confidence
O	1020	1028	interval
O	1029	1030	[
O	1030	1032	CI
O	1032	1033	]
O	1033	1034	:
O	1035	1037	41
O	1037	1038	%
O	1038	1039	-
O	1039	1041	69
O	1041	1042	%
O	1042	1043	)
O	1043	1044	.

O	1045	1053	Compared
O	1054	1058	with
O	1059	1062	the
O	1063	1068	every
O	1068	1069	-
O	1069	1070	3
O	1070	1071	-
O	1071	1076	weeks
O	1077	1085	schedule
O	1085	1086	,
O	1087	1090	the
O	1091	1097	weekly
O	1098	1112	administration
O	1113	1121	achieved
O	1122	1128	higher
B-outcome	1129	1132	pCR
O	1133	1134	(
B-cv-bin-percent	1134	1136	41
I-cv-bin-percent	1136	1137	%
O	1138	1140	vs
O	1140	1141	.
B-iv-bin-percent	1142	1144	69
I-iv-bin-percent	1144	1145	%
O	1145	1146	;
O	1147	1148	p
O	1149	1150	=
O	1151	1152	.
O	1152	1154	03
O	1154	1155	)
O	1155	1156	.

O	1157	1162	After
O	1163	1173	adjustment
O	1174	1177	for
O	1178	1186	clinical
O	1187	1190	and
O	1191	1203	pathological
O	1204	1211	factors
O	1211	1212	,
O	1213	1216	the
O	1217	1223	weekly
O	1224	1238	administration
O	1239	1242	was
O	1243	1247	more
B-outcome	1248	1257	effective
O	1258	1262	than
O	1263	1266	the
O	1267	1272	every
O	1272	1273	-
O	1273	1274	3
O	1274	1275	-
O	1275	1280	weeks
O	1281	1289	schedule
O	1289	1290	,
O	1291	1295	with
O	1296	1302	hazard
O	1303	1308	ratio
O	1309	1311	of
O	1312	1313	0
O	1313	1314	.
O	1314	1315	3
O	1316	1317	(
O	1317	1319	95
O	1319	1320	%
O	1321	1323	CI
O	1323	1324	:
O	1325	1326	0
O	1326	1327	.
O	1327	1328	1
O	1328	1329	-
O	1329	1330	0
O	1330	1331	.
O	1331	1332	9
O	1332	1333	;
O	1334	1335	p
O	1336	1337	=
O	1338	1339	.
O	1339	1341	03
O	1341	1342	)
O	1342	1343	.

O	1344	1357	Interestingly
O	1357	1358	,
O	1359	1365	weekly
O	1366	1380	administration
O	1381	1389	resulted
O	1390	1392	in
O	1393	1397	high
B-outcome	1398	1401	pCR
I-outcome	1402	1407	rates
O	1408	1410	in
O	1411	1415	both
O	1416	1423	luminal
O	1423	1424	-
O	1424	1425	B
O	1426	1427	(
O	1427	1431	HER2
O	1431	1432	-
O	1432	1440	positive
O	1440	1441	)
O	1442	1445	and
O	1446	1451	ERBB2
O	1451	1452	+
O	1453	1459	tumors
O	1460	1461	(
B-cv-bin-percent	1461	1463	67
I-cv-bin-percent	1463	1464	%
O	1465	1467	vs
O	1467	1468	.
B-iv-bin-percent	1469	1471	71
I-iv-bin-percent	1471	1472	%
O	1472	1473	;
O	1474	1475	p
O	1476	1477	=
O	1478	1479	.
O	1479	1481	78
O	1481	1482	)
O	1482	1483	,
O	1484	1491	whereas
B-outcome	1492	1499	luminal
I-outcome	1499	1500	-
I-outcome	1500	1501	B
I-outcome	1502	1503	(
I-outcome	1503	1507	HER2
I-outcome	1507	1508	-
I-outcome	1508	1516	positive
I-outcome	1516	1517	)
I-outcome	1518	1524	tumors
O	1525	1534	benefited
O	1535	1539	less
O	1540	1544	from
O	1545	1548	the
O	1549	1554	every
O	1554	1555	-
O	1555	1556	3
O	1556	1557	-
O	1557	1562	weeks
O	1563	1571	schedule
O	1572	1580	compared
O	1581	1585	with
O	1586	1589	the
O	1590	1595	ERBB2
O	1595	1596	+
O	1597	1603	tumors
O	1604	1605	(
B-cv-bin-percent	1605	1607	21
I-cv-bin-percent	1607	1608	%
O	1609	1611	vs
O	1611	1612	.
B-iv-bin-percent	1613	1615	62
I-iv-bin-percent	1615	1616	%
O	1616	1617	,
O	1618	1619	p
O	1620	1621	=
O	1622	1623	.
O	1623	1625	03
O	1625	1626	)
O	1626	1627	.

O	1628	1633	These
O	1634	1641	results
O	1642	1648	remain
O	1649	1654	after
O	1655	1667	multivariate
O	1668	1678	adjustment
O	1678	1679	,
O	1680	1687	showing
O	1688	1694	weekly
O	1695	1709	administration
O	1710	1713	was
O	1714	1718	more
O	1719	1728	effective
O	1729	1731	in
O	1732	1735	the
O	1736	1743	luminal
O	1743	1744	-
O	1744	1745	B
O	1746	1747	(
O	1747	1751	HER2
O	1751	1752	-
O	1752	1760	positive
O	1760	1761	)
O	1762	1770	subgroup
O	1771	1772	(
O	1772	1773	p
O	1774	1775	=
O	1776	1777	.
O	1777	1779	02
O	1779	1780	)
O	1781	1784	but
O	1785	1788	not
O	1789	1791	in
O	1792	1795	the
O	1796	1801	ERBB2
O	1801	1802	+
O	1803	1811	subgroup
O	1812	1813	(
O	1813	1814	p
O	1815	1816	=
O	1817	1818	.
O	1818	1820	50
O	1820	1821	)
O	1821	1822	.

O	1823	1824	A
O	1825	1829	more
O	1830	1838	frequent
O	1839	1853	administration
O	1854	1859	might
O	1860	1867	improve
O	1868	1871	the
O	1872	1883	possibility
O	1884	1886	of
O	1887	1898	eradicating
O	1899	1907	invasive
O	1908	1914	cancer
O	1915	1917	in
O	1918	1921	the
O	1922	1928	breast
O	1929	1932	and
O	1933	1939	axilla
O	1939	1940	,
O	1941	1951	especially
O	1952	1954	in
O	1955	1958	the
O	1959	1966	luminal
O	1966	1967	-
O	1967	1968	B
O	1969	1970	(
O	1970	1974	HER2
O	1974	1975	-
O	1975	1983	positive
O	1983	1984	)
O	1985	1992	subtype
O	1992	1993	.

O	1994	2001	Further
O	2002	2009	studies
O	2010	2012	to
O	2013	2021	validate
O	2022	2025	our
O	2026	2034	findings
O	2035	2038	are
O	2039	2048	warranted
O	2048	2049	.
